Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD

被引:0
|
作者
Nobuharu Tamaki
Veeral Ajmera
Rohit Loomba
机构
[1] University of California San Diego,NAFLD Research Center, Division of Gastroenterology and Hepatology, Department of Medicine
[2] Musashino Red Cross Hospital,Department of Gastroenterology and Hepatology
[3] University of California San Diego,The Herbert Wertheim School of Public Health and Human Longevity Science
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD). The non-invasive quantification of liver fat is now possible due to advances in imaging modalities. Emerging data suggest that high levels of liver fat and its temporal change, as measured by quantitative non-invasive methods, might be associated with NAFLD progression. Ultrasound-based modalities have moderate diagnostic accuracy for liver fat content and are suitable for screening. However, of the non-invasive imaging modalities, MRI-derived proton density fat fraction (MRI-PDFF) has the highest diagnostic accuracy and is used for trial enrolment and to evaluate therapeutic effects in early-phase clinical trials in nonalcoholic steatohepatitis (NASH). In patients with NAFLD without advanced fibrosis, high levels of liver fat are associated with rapid disease progression. Furthermore, changes on MRI-PDFF (≥30% decline relative to baseline) are associated with NAFLD activity score improvement and fibrosis regression. However, an inverse association exists between liver fat and complications of cirrhosis. Liver fat decreases as liver fibrosis progresses towards cirrhosis, and the clinical importance of quantitative measurements of liver fat differs by NAFLD status. As such, patients with NAFLD should be stratified by fibrosis severity to investigate the utility of quantitative measurements of liver fat for assessing NAFLD progression and prognosis.
引用
收藏
页码:55 / 66
页数:11
相关论文
共 50 条
  • [31] Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients
    Shen, Feng
    Zheng, Rui-Dan
    Mi, Yu-Qiang
    Wang, Xiao-Ying
    Pan, Qin
    Chen, Guang-Yu
    Cao, Hai-Xia
    Chen, Ming-Li
    Xu, Liang
    Chen, Jian-Neng
    Cao, Yi
    Zhang, Rui-Nan
    Xu, Lei-Ming
    Fan, Jian-Gao
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (16) : 4702 - 4711
  • [32] Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome
    Chakraborty, Semanti
    Ganie, Mohd Ashraf
    Masoodi, Ibrahim
    Jana, Manisha
    Shalimar
    Gupta, Nandita
    Sofi, Nighat Yaseen
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 151 (04) : 333 - 341
  • [33] CHARACTERISTICS OF NON-INVASIVE SURROGATES OF HEPATIC STEATOSIS AMONG PERSONS LIVING WITH HIV
    Duarte, Maria
    Price, Jennifer C.
    Ma, Yifei
    Scherzer, Rebecca
    Noworolski, Susan
    Korn, Natalie
    Tien, Phyllis C.
    HEPATOLOGY, 2020, 72 : 900A - 901A
  • [34] Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients
    Feng Shen
    Rui-Dan Zheng
    Yu-Qiang Mi
    Xiao-Ying Wang
    Qin Pan
    Guang-Yu Chen
    Hai-Xia Cao
    Ming-Li Chen
    Liang Xu
    Jian-Neng Chen
    Yi Cao
    Rui-Nan Zhang
    Lei-Ming Xu
    Jian-Gao Fan
    World Journal of Gastroenterology, 2014, 20 (16) : 4702 - 4711
  • [35] HEPATIC XE-133 RETENTION - NON-INVASIVE DIAGNOSTIC TEST FOR STEATOSIS
    AHMAD, ML
    PERRILLO, RP
    SUNWOO, YL
    DONATI, RM
    GASTROENTEROLOGY, 1977, 73 (05) : 1211 - 1211
  • [36] Non-invasive diagnosis of steatosis and fibrosis
    Castera, L.
    DIABETES & METABOLISM, 2008, 34 (06) : 674 - 679
  • [37] Non-invasive clinical methods of vascular investigation
    Kobalava, Zh. D.
    Kotovskaya, Yu. V.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2009, 8 (04): : 5 - 7
  • [38] NON-INVASIVE METHODS IN CLINICAL-PHARMACOLOGY
    PROUS, JR
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1984, 6 (11): : 715 - 715
  • [39] The diagnostic accuracy of non-invasive serum biomarkers for hepatic fibrosis in a cohort of patients with NAFLD
    Pecoraro, V.
    Cuccorese, M.
    Gabrielli, F.
    Andreone, P.
    Nascimbeni, F.
    Trenti, T.
    CLINICA CHIMICA ACTA, 2024, 558 : 76 - 76
  • [40] Nuclear imaging methods for non-invasive drug monitoring
    Bhatnagar, A
    Hustinx, R
    Alavi, A
    ADVANCED DRUG DELIVERY REVIEWS, 2000, 41 (01) : 41 - 54